Novo Nordisk Inc v. Lupin Ltd D

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Lupin Ltd. (India)
  • Plaintiff's Counsel: Fenwick & West LLP
• Case Identification: 3:23-cv-04027, D.N.J., 07/27/2023
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant conducts business in the state, has engaged in systematic and continuous contacts, and has previously litigated and consented to venue in the district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Victoza® (liraglutide) product constitutes an act of infringement of two patents related to the drug's formulation and its injection device.
• Technical Context: The dispute involves technology in the field of injectable peptide formulations for diabetes treatment and the mechanical design of pen-style injection devices used for their administration.
• Key Procedural History: The litigation was triggered by Defendant's filing of an ANDA with the U.S. Food and Drug Administration, which included a Paragraph IV Certification asserting that Plaintiff's patents are invalid, unenforceable, or will not be infringed. Plaintiff filed this suit within the 45-day statutory window following receipt of Defendant's notice letter, triggering a potential 30-month stay of FDA approval for the generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and For Use in Injection Devices"

The Invention Explained

• Problem Addressed: The patent's background section describes how common isotonicity agents, such as mannitol, can cause manufacturing problems by crystallizing and forming deposits on production equipment and in the final drug product Compl., Ex. A, '833 Patent, col. 1:30-38 These deposits can reduce production yield and, critically, cause clogging in the fine needles of injection devices used by patients Compl., Ex. A, '833 Patent, col. 1:42-45
• The Patented Solution: The invention claims to solve this problem by replacing mannitol with propylene glycol as the isotonicity agent in a peptide formulation Compl., Ex. A, '833 Patent, abstract This substitution is asserted to reduce deposits during production and minimize clogging of injection devices, thereby improving both manufacturing efficiency and the reliability of the drug delivery device for the end user Compl., Ex. A, '833 Patent, col. 1:50-54
• Technical Importance: The invention addresses a practical and significant challenge in the large-scale manufacturing and clinical use of injectable biologic drugs, where formulation stability and reliable delivery are paramount.

Key Claims at a Glance

• The complaint asserts claims 1-31 of the '833 patent Compl. ¶22 Independent claim 1 is representative of the formulation claims.
• Claim 1 Elements:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist,
  • a disodium phosphate dihydrate buffer and
  • propylene glycol,
  • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml and
  • wherein said formulation has a pH of from about 7.0 to about 10.0.

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

• Problem Addressed: In pen-style injection devices, a user pushes a button to administer a dose. The patent explains that during this action, the push button and the internal driving mechanism often rotate relative to each other, creating friction Compl., Ex. B, '893 Patent, col. 1:49-52 This friction increases the force the user must apply to inject the dose, which can be a challenge for some patients Compl., Ex. B, '893 Patent, col. 1:52-54
• The Patented Solution: The invention describes a specific mechanical connection between the push button and the driving part that is designed to minimize this rotational friction. The core of the solution is a "pivot bearing" formed between the two components, which minimizes the surface area of interaction and the radius of the resulting friction force Compl., Ex. B, '893 Patent, abstract Compl., Ex. B, '893 Patent, col. 1:55-58 Figure 1 illustrates the push button (10) engaging a protrusion on the driving part (20) at a pivot point (18, 22).
• Technical Importance: The invention seeks to improve the ergonomics and usability of injection pens by reducing the actuation force, making the devices easier for patients to operate.

Key Claims at a Glance

• The complaint asserts claims 1-6 of the '893 patent Compl. ¶28 Claim 1 is the sole independent claim.
• Claim 1 Elements:
  • A push button connection for an injection device comprising:
  • a push button mountable on a driving part being rotatable relatively to the push button,
  • which push button further comprises a bore with a bottom surface,
  • which bore surrounds a protrusion on the driving part which has a top surface,
  • wherein a pivot bearing is formed between the bottom surface and the top surface,
  • wherein when a user presses the push button the force is directed toward the driving part and the driving part rotates relative to the push button.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Lupin's Product," identified as a generic version of liraglutide injection solution, 18 mg/3 ml (6 mg/ml), for which Defendant has filed ANDA No. 215421 Compl. ¶10 Compl. ¶17 The infringement allegations also implicate the injection device intended for use with Lupin's Product Compl. ¶28

Functionality and Market Context

• Lupin's Product is intended to be a generic equivalent of Novo Nordisk's Victoza®, a widely used treatment for type 2 diabetes Compl. ¶1 Compl. ¶17 The ANDA filing asserts that Lupin's product is bioequivalent to Victoza® Compl. ¶18
• The complaint alleges that Lupin intends to commercially manufacture, use, offer for sale, and sell this product in the United States upon receiving FDA approval Compl. ¶10

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or specific factual allegations mapping elements of the accused product to the patent claims. The infringement counts are based on the statutory act of filing an ANDA under 35 U.S.C. § 271(e)(2)(A) Compl. ¶21 Compl. ¶27

'833 Patent Infringement Allegations

The complaint alleges that Lupin's proposed generic liraglutide product, as described in its ANDA, is a pharmaceutical formulation that will infringe claims 1-31 of the '833 Patent Compl. ¶22 The central theory is that to be a bioequivalent generic of Victoza®, Lupin's Product must necessarily contain the claimed combination of a GLP-1 agonist, propylene glycol, and a specific buffer at the claimed pH and concentration ranges.

• Identified Points of Contention:
  • Factual Question: The primary dispute will be factual and resolved through discovery of Lupin's confidential ANDA. The key question is whether the formulation described in the ANDA contains a GLP-1 agonist (liraglutide), propylene glycol, and a disodium phosphate dihydrate buffer, all within the concentration and pH ranges specified in the asserted claims.

'893 Patent Infringement Allegations

The complaint alleges that the manufacture, use, or sale of Lupin's Product would infringe claims 1-6 of the '893 Patent Compl. ¶28 This implies that the injection device Lupin intends to market for use with its generic drug incorporates the patented push button connection.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Factual Question: The analysis will depend entirely on the mechanical design of the injection device described in Lupin's ANDA. The central question is whether that device's push button and driving mechanism are rotatable relative to each other and are connected via a "pivot bearing" as required by claim 1.
  • Scope Question: A potential dispute may arise over the meaning of "pivot bearing." The case may turn on whether the interface in Lupin's device performs the specific friction-reducing function described in the patent, which could raise questions about the proper construction of this term.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of key claim terms for the '833 patent.

For the '893 patent, a central term for construction emerges:

• The Term: "pivot bearing" (from claim 1)
• Context and Importance: This term is the structural heart of the claimed invention for reducing injection force. The outcome of the infringement analysis for the '893 patent will likely depend on whether the connection in Defendant's accused device falls within the scope of this term. Practitioners may focus on this term because it links the claimed structure to the invention's stated functional purpose of minimizing friction.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The language of claim 1 broadly recites "a pivot bearing is formed between the bottom surface [of the button's bore] and the top surface [of the driving part's protrusion]" Compl., Ex. B, '893 Patent, claim 1 This could be argued to cover any interface that allows for pivoting motion between two surfaces under axial load.
  • Evidence for a Narrower Interpretation: The specification describes the purpose of the pivot bearing is to ensure "the surface area of interaction between the two objects can be minimized and the radius of the resulting friction force can be kept at a minimum" Compl., Ex. B, '893 Patent, col. 1:55-58 The detailed description further specifies an embodiment where the bottom surface of the bore has a "raised pointer forming a pivot 18" Compl., Ex. B, '893 Patent, col. 3:60-63 This language may support an argument that the term "pivot bearing" is limited to structures specifically designed to create point- or small-area contact to achieve the friction-reduction objective, rather than any simple surface-to-surface contact.

VI. Other Allegations

• Willful Infringement: The complaint alleges that Lupin was aware of both the '833 patent and the '893 patent at the time it submitted its ANDA Compl. ¶25 Compl. ¶31 This allegation of pre-suit knowledge, derived from the statutory requirement for an ANDA filer to address patents listed in the FDA's Orange Book, forms the basis for Plaintiff's request for a finding of an exceptional case and an award of attorneys' fees Compl. ¶25 Compl. ¶31 Compl., Prayer for Relief ¶F

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two central, fact-dependent questions stemming from the confidential contents of Defendant's ANDA filing.

• A core issue will be one of compositional identity: Does the formulation for the proposed generic product, as detailed in Lupin's ANDA, contain the exact combination of excipients-specifically propylene glycol as an isotonicity agent and a disodium phosphate dihydrate buffer-at the concentrations and pH required by the claims of the '833 patent?
• A second core issue will be one of structural correspondence: Does the injection device that Lupin plans to market with its generic drug employ a push button mechanism with the specific "pivot bearing" and relative rotational movement between the button and driving part, as claimed in the '893 patent? The answer to this may hinge on the court's construction of the term "pivot bearing."